Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Cybin Inc (NY: CYBN )

0.2700 -0.0300 (-10.00%)
Streaming Delayed Price Updated: 2:38 PM EDT, Jun 6, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Cybin Inc

< Previous 1 2
...
14 15 16 17 18 19 20 21 Next >
Mind Medicine, Small Pharma Among Top Psychedelic Movers Of Today
GAINERS: Small Pharma (OTC: 
Via Benzinga
Mind Medicine, Mindset Pharma Among Top Psychedelic Movers Of Today
GAINERS: Mind Medicine (NASDAQ: 
Via Benzinga
Psychedelic Stock Gainers And Losers From January 24, 2022
GAINERS: Field Trip Health (NASDAQ: 
Via Benzinga
Weekend Update: Only 2 Psychedelic Drug Stocks Are Up YTD
This article updates the performances of the 16 largest capitalized clinical-stage psychedelic and marijuana drug companies researching the treatment of a wide variety of mental illnesses out of a... 
Via Talk Markets
Psychedelic Stock Gainers And Losers From January 21, 2022
GAINERS: GH Research (NASDAQ: 
Via Benzinga
Psychedelic Stock Gainers And Losers From January 20, 2022
GAINERS: Small Pharma (OTC: 
Via Benzinga
Revive Therapeutics, GH Research Among Top Psychedelic Movers Of Today
GAINERS: Revive Therapeutics (OTC: 
Via Benzinga
Psychedelic Stock Gainers And Losers From January 18, 2022
GAINERS: Cybin (AMEX: 
Via Benzinga
Psyched: Delix Raises $30M, New Ketamine Study For Alcohol Use Disorder, FDA Approves Ketamine Trial For ALS
New Awakn Study Shows Ketamine Has Potential To Treat Alcoholism Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: 
Via Benzinga
Cybin Notes 'Milestone' Step with USPTO Notice of Allowance for CYB004
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advi... 
Via Benzinga
Psychedelics Biotech Companies Mark New Milestones In Drug Development Pipelines: Field Trip, Cybin and Wesana
On Tuesday, three public companies in the psychedelics/biotech space announced significant milestones in their drug development pipelines. 
Via Benzinga
Cybin CEO Participation in Upcoming Events Recognizes Company Expertise
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advi... 
Via Benzinga
Why Cybin Shares Are Rising
Cybin Inc (NASDAQ: CYBN) shares are trading higher after the company announced an Institutional Review Board granted approval for a Cybin-sponsored feasibility study using Kernel... 
Via Benzinga
Cybin Highlights Adelia's Milestone Achievement
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. Cybin (NYSE: CYBN), a biotechnology... 
Via Benzinga
Pure-Play Marijuana- & Psychedelic Compounds-Based Drug Stocks Index Is Down By 66% From 2021 High
There are 16 remaining constituents of our Marijuana & Psychedelic Compounds-Based Drug Stocks Index is now DOWN -65.9% from its highs in 2021. Here are the details for each of its constituents. 
Via Talk Markets
Cybin Witnessing Advancement in R&D Pipeline
Cybin (NYSE: CYBN), a life sciences company advancing psychedelic therapeutics for various psychiatric and neurological conditions, recently released its financial and operating... 
Via Benzinga
Steep Decline In Cannabis & Psychedelic Compounds-Based Drug Stocks Continues: DOWN -16.6% MTD
All 12 constituents in the Marijuana & Psychedelic Compounds-Based Drug Stocks Index continue to decline. How do their performances compare month-to-date and YTD? 
Via Talk Markets
Marijuana & Psychedelic Compounds-Based Drug Stocks Now Down -16% YTD
A look at which index has done the best so far in December: the Marijuana Drug Stocks Index or the Psychedelic Compounds-Based Drug Stocks Index. 
Via Talk Markets
Cybin Receives Notice of Allowance from U.S. Patent Office
Cybin (NYSE: CYBN), a biotechnology company focused on progressing psychedelic therapeutics, has been awarded a Notice of Allowance from the U.S. Patent and Trademark Office (... 
Via Benzinga
Cybin Developing Safer, More Effective Psilocybin Therapies
Cybin (NYSE: CYBN), a life sciences company advancing psychedelic therapeutics for various psychiatric and neurological conditions, recently announced positive results from a... 
Via Benzinga
Cybin to Fund, Support Psychedelic Clinic at Manhattan Hospital
Company receives grant to fund clinic for marginalized, underserved NYC communities New clini... 
Via Benzinga
Psilera's DMT-Derived Drug Sees Positive Results in Pre-Clinical Study
Psilera is a Florida-based biotechnology company focused on developing drugs to treat mental disorders using non-hallucinogenic derivatives from psychedelic compounds. The... 
Via Benzinga
Topics Derivatives
Exposures Derivatives
Cybin Touts Highlights of 'Transformative' Second-Quarter Performance
The report notes significant and swift advancements in the company R&D pipeline and overall business Preliminary data indicates CYB003 may provide significant treatment... 
Via Benzinga
Cybin Announces FDA Approvals, Participation in Conference
Cybin (NYSE: 
Via Benzinga
Exposures Product Safety
Psilocybin Trials For COVID-Related Distress Of Healthcare Professionals Could Validate New Psychotherapy Model
Cybin (NYSE:CYBN), a biotech company focused on progressing ... 
Via Benzinga
Cybin To Test Psychedelic-Assisted Psychotherapy For COVID-Related Distress
The FDA authorized an investigator-initiated Phase 2 trial evaluating Cybin Inc's (NYSE: CYBN) psychedelic-assisted psychotherapy with psilocybin for... 
Via Benzinga
Exposures Product Safety
Cybin Supports Psychedelic Treatment Clinic Through Grant
Cybin (NYSE: CYBN), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics(TM),” today announced it has awarded a grant for the first... 
Via Benzinga
NY's Lenox Hill Hospital With Cybin-Awarded Grant Will Provide Psychedelic Therapy To City's Underserved
Psychedelic therapy company, Cybin Inc. (NEO: CYBN) (NYSE: 
Via Benzinga
Psychedelic Drug Stocks Continued To Decline Last Week
The 12 constituents in our Pure-Play Psychedelic Compounds-Based Drug Stocks Index declined -5.7% last week; it's now -16.1% so far in November. 
Via Talk Markets
Cybin 'One Step Closer' to Creating Best Therapy for Mental Health
Company releases positive results from a pre-clinical study focusing on psilocybin program CYB003 Multiple academic studies have shown that psilocybin may have the potential to... 
Via Benzinga
< Previous 1 2
...
14 15 16 17 18 19 20 21 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.